Category: Covid-19

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-20 December 2024 and includes updates on Cyclone Chido, Mpox due to monkeypox virus clade I and II, SARS-CoV-2 variant classification, Overview of respiratory virus epidemiology in the EU/EEA, Marburg virus disease and Avian influenza A(H5N1).

Almost all countries reporting data to ECDC are observing sharp increases in indicators of both influenza and respiratory syncytial virus (RSV) activity, with a visible impact in secondary care.

This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 4.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0.

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7-13 December 2024 and includes updates on measles, chikungunya, dengue, avian influenza, mpox, West Nile virus, circulating vaccine-derived poliovirus type 2, hepatitis A, suspected viral haemorrhagic fever in Sierra Leone, an unknown disease in the Democratic Republic of Congo, and an overview…

In EU/EEA countries, while SARS-CoV-2 activity remains low, both influenza and RSV activity are increasing. Vaccination campaigns have started in many EU/EEA countries. People who are eligible for vaccination, particularly those at higher risk of severe outcomes, are encouraged to get vaccinated.

ECDC has launched an online platform, RespiCompass, which uses mathematical modelling to simulate respiratory disease dynamics under different scenarios.

In EU/EEA countries, respiratory syncytial virus (RSV) activity remains high. Influenza activity remains low but is slowly increasing. SARS-CoV-2 activity remains at low levels.

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 30 November – 6 December2024 and includes updates on increases in respiratory infections due to Mycoplasma pnemoniae in the EU/EEA, SARS-CoV-2 variant classification, Influenza A(H5N1), Avian influenza, Middle East respiratory syndrome, an unknown disease in the Democratic Republic of the Congo, mpox,…

This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.

This document reports the results of prospective monitoring of COVID-19 vaccine effectiveness.